Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.65 - $34.92
Previous CloseN/A
Volume124.06K
Average Volume (3M)140.99K
Market Cap
$136.83M
Enterprise Value$63.28M
Total Cash (Recent Filing)$301.18M
Total Debt (Recent Filing)$48.85M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 06, 2025EPS Estimate
-3.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding14,808,078
10 Day Avg. Volume38,304
30 Day Avg. Volume140,989
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)8.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue260.40
Enterprise Value/Gross Profit973.49
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$11.00Price Target Upside19.05% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma Announces Promising CAR T-Cell Trial Data
PremiumCompany Announcements
Lyell Immunopharma Expands Board, Appoints New Director
Bulls Say, Bears Say
Bulls Say
Financial ResourcesLyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.
Regulatory SupportRMAT designation for LYL314 is a positive sign in turbulent times at the FDA.
Bears Say
Financial PerformanceLyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.
Market CompetitionThe CD19-targeted CAR-T space is considered crowded and may not support another entrant with the current under $3 billion aggregated annual sales across competitors.
Strategic UncertaintyThe decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.
Ownership Overview
15.94% Insiders
7.07% Mutual Funds
19.78% Other Institutional Investors
50.74% Public Companies and
Individual Investors
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $7.65 and its highest was $34.92 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $136.83M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Aug 06, 2025 which is in 16 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on May 13, 2025. The company reported -$1.86 earnings per share for the quarter, beating the consensus estimate of -$3.6 by $1.74.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -3.58.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 14,808,078 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$1.86 in its last earnings report, beating expectations of -$3.6. Following the earnings report the stock price went down -3.585%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
Lyell Immunopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$11.00 (19.05% Upside)
$11.00 (19.05% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 473.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.65%
12-Months-Change
Fundamentals
Return on Equity
-71.20%
Trailing 12-Months
Asset Growth
-38.09%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$11.00
▲(19.05%Upside)